- Clone
- A21044E (See other available formats)
- Regulatory Status
- RUO
- Other Names
- B cell maturation antigen (BCMA), tumor necrosis factor receptor superfamily member 17, CD269
- Isotype
- Mouse IgG2b, κ
-
Biotinylated recombinant human TNFRSF17-Fc chimera (Cat. No. 796404) (black circles) binds to immobilized recombinant human APRIL / TNFSF13 protein. Ultra-LEAF™ purified anti-human CD269 (BCMA) (clone A21044E) (purple squares) inhibits the binding in a dose-dependent manner, whereas the Ultra-LEAF™ purified mouse IgG2b, κ isotype control (Cat. No. 401216) (gray triangles) does not have the effect. This antibody blocks the binding of 0.05 µg/mL biotinylated recombinant human TNFRSF17-Fc chimera to 0.3 µg/mL immobilized recombinant human APRIL/TNFSF13. ND50 range: 0.05 - 0.3 µg/mL.
| Cat # | Size | Price | Quantity Check Availability | ||
|---|---|---|---|---|---|
| 652153 | 100 µg | $405.00 | |||
| 652154 | 1 mg | $1045.00 | |||
Human TNFRSF17 (B cell maturation antigen, BCMA) is a type I attached membrane protein of 184 amino acids, with a conserved motif of six cysteines in the N-terminal end, consistent with the formation of a cysteine repeat motif found in the extracellular domain of TNFRs. Overexpression of TNFRSF17 in 293 cells activates NF-kappa B, Elk-1, c-Jun N-terminal kinase, and the p38 mitogen-activated protein kinase, after its association with TNF Receptor-Associated Factor (TRAF) 1, TRAF2, and TRAF3. Soluble forms of TACI (TNFRSF13B) and TNFRSF17 bind to BAFF (TNFSFL13B) and APRIL (TNFSFL13A). TNFRSF17-APRIL interaction has higher affinity than TNFRSF17-BAFF interaction. Analysis of TNFRSF17 knockout mice (TNFRSF17−/−) demonstrates no differences in the steady-state frequencies or composition of peripheral B cell subsets (immature, marginal zone, follicular, B1). PBMCs from mice with Sjogren’s-like syndrome demonstrates upregulated TNFRSF17 expression. TNFRSF17 is also increased in patients with Sjogren’s syndrome, rheumatoid arthritis, and on B cells from SLE patients. Patients with multiple myeloma show elevated levels of TNFRSF17 in serum, and it correlated with the proportion of plasma cells in bone marrow biopsies and clinical status. Serum TNFRSF17 levels in considered a novel biomarker to predict outcomes for multiple myeloma patients.
Product Details
- Verified Reactivity
- Human
- Antibody Type
- Monoclonal
- Host Species
- Mouse
- Immunogen
- Recombinant Human TNFRSF17-Fc Chimera
- Formulation
- 0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
- Preparation
- The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
- Concentration
- The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
- Application
-
Block - Quality tested
- Recommended Usage
-
Each lot of this antibody is quality control tested by blocking the binding of 0.05 µg/mL biotinylated human TNFRSF17-Fc chimera (Cat. No. 796404) to immobilized 0.3 µg/mL recombinant human APRIL / TNFSF13. ND50 range: 0.05 - 0.3 µg/mL. It is recommended that the reagent be titrated for optimal performance for each application.
- RRID
-
AB_3662332 (BioLegend Cat. No. 652153)
AB_3662332 (BioLegend Cat. No. 652154)
Antigen Details
- Structure
- Homodimer
- Distribution
-
Resting and activated B cells, malignant B lymphocytes, plasma cells
- Function
- Maintains the peripheral B cell population and survival of long-lived bone marrow plasma cells. Soluble BCMA acts as a decoy receptor for APRIL. TNFRSF17 mRNA is stimulated by IL-4 and IL-6 in murine B cells.
- Interaction
- Monocytes, macrophages, T cells, and dendritic cells
- Ligand/Receptor
- TNFSF13 (APRIL), TNFSF (BAFF)
- Cell Type
- B cells, Plasma cells
- Biology Area
- Immunology
- Molecular Family
- CD Molecules
- Antigen References
-
- Madry C, et al. 1998. Int Immunol. 10:1693-702.
- Hatzoglou A, et al. 2000. J Immunol. 165:1322-30.
- Rennert P, et al. 2000. J Exp Med. 192:1677-84.
- Wallweber HJ, et al. 2004. J Mol Biol. 343:283-90.
- O'Connor BP, et al. 2004. J Exp Med. 199:91-8.
- Kim J, et al. 2011. Autoimmunity. 44:69-81.
- Coqueri CM, and Erickson LD. 2012. Crit Rev Immunol. 32:287-305.
- Laurent SA, et al. 2015. Nature Commun. 6:7333.
- Ghermezi M, et al. 2017. Hematologica. 102:785-795.
- Gene ID
- 608 View all products for this Gene ID
- UniProt
- View information about CD269 on UniProt.org
Other Formats
View All CD269 Reagents Request Custom Conjugation| Description | Clone | Applications |
|---|---|---|
| Ultra-LEAF™ Purified anti-human CD269 (BCMA) | A21044E | Block |
Compare Data Across All Formats
This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.
-
Ultra-LEAF™ Purified anti-human CD269 (BCMA)
Biotinylated recombinant human TNFRSF17-Fc chimera (Cat. No....